MOTs-c: what the research says.
Last updated May 22, 2026
A 16-amino-acid peptide encoded inside the mitochondrial genome itself, identified by the Cohen lab at USC in 2015. The research base centers on AMPK activation, insulin sensitivity, and a striking overlap with the metabolic effects of exercise. Here is what the published evidence supports, and where the boundaries sit.
Regulatory notice: MOTs-c is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. MOTs-c is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including MOTs-c. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that MOTs-c’s legal status has changed or that PepScribe will offer it in the future.
What MOTs-c is.
MOTs-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide whose coding sequence sits inside the mitochondrial 12S ribosomal RNA gene. That detail matters: most peptides are translated from nuclear DNA, while MOTs-c is one of a small class of mitochondrial-derived peptides (MDPs) whose open reading frames live in the mitochondrial genome itself. Other members of this class include humanin and the SHLP family.
The peptide was identified and characterized by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California. Their initial paper, Lee et al., published in Cell Metabolism in 2015 (volume 21, issue 3), described MOTs-c as a regulator of insulin sensitivity and metabolic homeostasis. Subsequent work from the Cohen lab and collaborators (including Kim, Mehta, and Reynolds) extended the picture to exercise physiology, aging, and tissue-level metabolic signaling.
A consistent observation across the research base is that circulating MOTs-c levels decline with age in humans, and that exercise rapidly elevates both circulating and skeletal-muscle MOTs-c. This is part of why the peptide is often described in the literature as exercise-mimetic, though that label is a shorthand for a more limited set of overlapping pathways, not a claim of equivalence.
How it works (proposed mechanisms).
Energy-sensing pathway
Lee et al. (2015, Cell Metabolism) showed that MOTs-c activates AMP -activated protein kinase (AMPK), the cellular energy sensor that responds to rising AMP:ATP ratios. AMPK activation increases glucose uptake in skeletal muscle, shifts substrate use toward fatty acid oxidation, and inhibits anabolic pathways (such as mTOR signaling) that consume ATP. This is the same central pathway engaged by metformin and by the metabolic stress of exercise.
Glucose homeostasis
In the original Lee et al. paper, exogenous MOTs-c administration in mice improved insulin sensitivity and reversed high-fat-diet-induced insulin resistance. The mechanism appears to involve increased glucose disposal in skeletal muscle, partial reversal of intramuscular lipid accumulation, and AMPK-dependent translocation of GLUT4 to the muscle cell membrane. These are preclinical findings, not human treatment outcomes.
Stress-responsive transcription
Kim et al. (2018, Cell Metabolism) demonstrated that under metabolic stress, MOTs-c translocates from the mitochondrion to the nucleus, where it binds chromatin and modulates the expression of nuclear-encoded stress-response genes. This positions MOTs-c as a retrograde signaling molecule, a way for the mitochondrion to communicate metabolic state back to the nuclear genome, which is a mechanism distinct from classic ligand-receptor peptide signaling.
Exercise-induced expression
Reynolds et al. (2021, Nature Communications) reported that acute exercise rapidly increases MOTs-c expression in human skeletal muscle and raises plasma MOTs-c, with a magnitude that suggests the peptide is part of the normal acute exercise response. The same group, and independently Yen et al. (2020, Aging), reported that baseline MOTs-c declines with age, which has fueled interest in MOTs-c as a candidate axis linking aging, mitochondrial function, and the loss of metabolic flexibility.
Most mechanistic data is preclinical (cell culture and rodent models) plus a small set of human observational and acute-exercise studies. Large randomized human trials of exogenous MOTs-c administration have not been published.
What the research suggests.
The published base for MOTs-c is roughly a decade old, concentrated in metabolism, aging, and exercise physiology, and dominated by preclinical and translational work from the Cohen lab at USC and a handful of collaborating groups.
Insulin sensitivity and glucose handling
Lee et al. (2015, Cell Metabolism) reported that exogenous MOTs-c improved glucose tolerance and insulin sensitivity in mouse models of diet-induced obesity. The proposed mechanism, AMPK-mediated GLUT4 translocation in skeletal muscle, parallels how metformin and exercise improve insulin signaling, though the magnitude and translation to human outcomes remain uncharacterized in randomized trials.
Aging and metabolic decline
Yen et al. (2020, Aging) reported that circulating MOTs-c declines with chronological age in humans, and that lower MOTs-c levels track with reduced exercise capacity. In aged mice, MOTs-c administration in published preclinical work has been associated with improved physical performance and metabolic markers. These are mechanistic and translational findings, not evidence that exogenous MOTs-c reverses age-related decline in humans.
Exercise physiology
Reynolds et al. (2021, Nature Communications) characterized MOTs-c as part of the acute response to exercise in human skeletal muscle, with measurable rises in muscle and plasma MOTs-c after a single bout of endurance exercise. This is one of the strongest pieces of human-level evidence in the MOTs-c literature, but it characterizes endogenous MOTs-c as an exercise-responsive signal, not exogenous MOTs-c as an exercise substitute.
Body composition and mitochondrial function
Preclinical work from the Cohen lab and collaborators has linked MOTs-c signaling to skeletal muscle mitochondrial biogenesis, fat oxidation, and resistance to diet-induced obesity in rodent models. The translational picture, whether exogenous MOTs-c administration in humans produces comparable shifts in body composition, has not been established in published controlled trials.
What is known versus what is not.
Reasonably established: MOTs-c exists as an endogenous mitochondrial-derived peptide in humans, declines with age, rises acutely with exercise, and engages AMPK in preclinical models. The molecular biology has been independently replicated, and the discovery literature in Cell Metabolism and Nature Communications sits in mainstream peer-reviewed journals.
Not established: that pharmacologic dosing of exogenous MOTs-c in humans produces durable improvements in insulin sensitivity, body composition, exercise capacity, or healthspan. Large randomized controlled trials in humans have not been published. Long-term safety, optimal dosing, route of administration, and pharmacokinetics in humans are all under-characterized.
The gap between the mechanistic picture (which is interesting) and the human clinical evidence (which is thin) is the central honest framing for any educational discussion of MOTs-c. The peptide is a credible research target, not a validated therapeutic.
Administration (research context).
In published preclinical research, MOTs-c is typically administered by injection (intraperitoneal in rodents, with subcutaneous protocols also described). Published human pharmacokinetic studies that would support a standardized dosing protocol have not been completed.
Compounded MOTs-c circulating in the gray market is most often offered as a lyophilized powder for reconstitution and subcutaneous injection. Without established clinical pharmacokinetic data, claimed dosing protocols in that setting are extrapolations from animal work, not evidence-based human regimens.
This is research context, not prescribing guidance. PepScribe does not currently offer MOTs-c as a peptide-direct product, and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations.
The human safety database for MOTs-c is small. The notes below summarize what the available preclinical and limited human data describe, plus general considerations for any research peptide.
Reported considerations
- Injection-site reactions (with subcutaneous administration)
- Transient changes in glucose handling, particularly in fasted state
- Headache or fatigue described anecdotally in user reports (not from controlled trials)
Safety profile notes
Preclinical toxicology and short-term rodent studies have not surfaced major safety signals at the doses studied, but long-term human safety, immunogenicity, and effects in people with established metabolic disease have not been characterized in published controlled trials. AMPK is a central energy-regulating pathway, and any sustained pharmacologic engagement of it warrants clinician oversight, especially in patients on insulin, sulfonylureas, metformin, or GLP-1 receptor agonists.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status.
MOTs-c has no FDA-approved drug application in the United States. It is not a dietary supplement, and it is not an FDA-approved therapeutic. As of the FDA’s April 15, 2026 update, MOTs-c sits in the post-Category-2 gray zone: removed from the explicit Category 2 prohibition list, but not placed on Category 1, pending review by the Pharmacy Compounding Advisory Committee (PCAC).
The practical effect is that some 503A compounding pharmacies are preparing MOTs-c on the legal theory that removal from Category 2 lifts the prior prohibition, while formal Category 1 placement (which is the unambiguous green light for compounding) has not been issued. This is a genuinely ambiguous regulatory posture, and any commercial framing should reflect that.
MOTs-c is not approved as a pharmaceutical in any major jurisdiction. Products labeled as MOTs-c outside of clinician-overseen 503A compounding are unregulated research chemicals without pharmaceutical-grade quality assurance.
Where MOTs-c fits in clinical practice.
Given the regulatory ambiguity and the limited human RCT data, the responsible clinical positioning for MOTs-c is consultation-first. A clinician evaluates goals (longevity-oriented metabolic support, insulin-sensitivity context, exercise capacity), reviews medical history (existing diabetes therapy, cardiovascular status, contraindications), and decides whether any peptide is appropriate. If a peptide is appropriate, the choice is made within the clinician’s formulary, not pre-selected by the patient based on a research peptide’s name.
For patients whose underlying interest is metabolic health, weight regulation, or insulin sensitivity, the better-validated, FDA-supported options (such as GLP-1-class therapies prescribed under shortage-period compounding) typically belong on the table first. MOTs-c, where appropriate at all, sits in a research -informed adjunct role, not as a primary metabolic intervention.
Semaglutide
GLP-1 receptor agonist with extensive randomized human trial data for weight regulation and glycemic support. Compounded under shortage-period rules, prescribed by a licensed clinician, and shipped from a US 503A compounding pharmacy.
Get startedNAD+
Supports cellular energy metabolism, sirtuin-mediated DNA repair, and mitochondrial function: pathways adjacent to the metabolic-aging axis that draws research interest to MOTs-c. Physician-prescribed and shipped to your door.
Get startedDeep dives
More on MOTs-c.
Research-backed articles covering specific topics in depth.
Talk to a clinician about your metabolic and longevity goals.
MOTs-c sits in a regulatory ambiguity with thin human RCT data. The right starting point is a consultation: a licensed clinician reviews your goals, history, and labs, then decides whether any peptide therapy fits, and which one.